Eli Lilly and Company (NYSE:LLY) Shares Bought by DeDora Capital Inc.

DeDora Capital Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,507 shares of the company’s stock after purchasing an additional 267 shares during the quarter. DeDora Capital Inc.’s holdings in Eli Lilly and Company were worth $2,221,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Calton & Associates Inc. lifted its holdings in shares of Eli Lilly and Company by 77.4% during the 3rd quarter. Calton & Associates Inc. now owns 1,836 shares of the company’s stock valued at $1,627,000 after acquiring an additional 801 shares in the last quarter. Oakworth Capital Inc. lifted its holdings in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Oakworth Capital Inc. now owns 3,884 shares of the company’s stock valued at $3,441,000 after acquiring an additional 79 shares in the last quarter. Maple Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. Maple Capital Management Inc. now owns 46,716 shares of the company’s stock valued at $41,388,000 after acquiring an additional 123 shares in the last quarter. Krane Funds Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 4.5% during the 3rd quarter. Krane Funds Advisors LLC now owns 438 shares of the company’s stock valued at $388,000 after acquiring an additional 19 shares in the last quarter. Finally, Foundations Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 44.2% during the 3rd quarter. Foundations Investment Advisors LLC now owns 33,055 shares of the company’s stock valued at $29,285,000 after acquiring an additional 10,129 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $3.58 during mid-day trading on Tuesday, reaching $909.71. The company had a trading volume of 266,867 shares, compared to its average volume of 2,963,623. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a 50 day moving average of $921.65 and a 200-day moving average of $859.57. The firm has a market cap of $864.59 billion, a price-to-earnings ratio of 133.45, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LLY shares. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Citigroup initiated coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. Finally, Bank of America increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.